APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Antibody Drug Conjugates

Compare research editions
View pricing & licenses

Selected research

Industry Research

Cancer Antibody Drug Conjugates Industry Research Report 2026

20 December 2025134 pages

Choose your research edition.

Industry ResearchCancer Antibody Drug Conjugates Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Antibody Drug Conjugates Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Cancer Antibody Drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Antibody Drug Conjugates Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Antibody Drug Conjugates Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Cancer Antibody Drug Conjugates market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Cancer Antibody Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Cancer Antibody Drug Conjugates is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Cancer Antibody Drug Conjugates is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, Viventia Biotechnologies, UCB, Stem CentRx, Seattle Genetics and Progenics Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Cancer Antibody Drug Conjugates market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Cancer Antibody Drug Conjugates Market by Company

Novartis

Merck

Roche

AbbVie

Viventia Biotechnologies

UCB

Stem CentRx

Seattle Genetics

Progenics Pharmaceuticals

PDL BioPharma

Nordic Nanovector

Millennium

Helix BioPharma

Bristol-Myers Squibb

Biotest AG

Biogen Idec

AbGenomics Corporation

Cancer Antibody Drug Conjugates Segment by Type

First & Second Generation ADCs

Third Generation ADCs

Cancer Antibody Drug Conjugates Segment by Application

Hospitals

Clinics

Others

Cancer Antibody Drug Conjugates Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Antibody Drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Antibody Drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Antibody Drug Conjugates.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Cancer Antibody Drug Conjugates manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Cancer Antibody Drug Conjugates by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Cancer Antibody Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Cancer Antibody Drug Conjugates Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Cancer Antibody Drug Conjugates Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers (2021-2026) Table 8. Global Cancer Antibody Drug Conjugates Revenue of Manufacturers (2021-2026) Table 9. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Cancer Antibody Drug Conjugates Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Cancer Antibody Drug Conjugates Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Cancer Antibody Drug Conjugates, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Cancer Antibody Drug Conjugates, Product Type & Application Table 14. Global Cancer Antibody Drug Conjugates Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Cancer Antibody Drug Conjugates by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novartis Company Information Table 19. Novartis Business Overview Table 20. Novartis Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Novartis Cancer Antibody Drug Conjugates Product Portfolio Table 22. Novartis Recent Developments Table 23. Merck Company Information Table 24. Merck Business Overview Table 25. Merck Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Merck Cancer Antibody Drug Conjugates Product Portfolio Table 27. Merck Recent Developments Table 28. Roche Company Information Table 29. Roche Business Overview Table 30. Roche Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Roche Cancer Antibody Drug Conjugates Product Portfolio Table 32. Roche Recent Developments Table 33. AbbVie Company Information Table 34. AbbVie Business Overview Table 35. AbbVie Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. AbbVie Cancer Antibody Drug Conjugates Product Portfolio Table 37. AbbVie Recent Developments Table 38. Viventia Biotechnologies Company Information Table 39. Viventia Biotechnologies Business Overview Table 40. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Portfolio Table 42. Viventia Biotechnologies Recent Developments Table 43. UCB Company Information Table 44. UCB Business Overview Table 45. UCB Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. UCB Cancer Antibody Drug Conjugates Product Portfolio Table 47. UCB Recent Developments Table 48. Stem CentRx Company Information Table 49. Stem CentRx Business Overview Table 50. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Stem CentRx Cancer Antibody Drug Conjugates Product Portfolio Table 52. Stem CentRx Recent Developments Table 53. Seattle Genetics Company Information Table 54. Seattle Genetics Business Overview Table 55. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Seattle Genetics Cancer Antibody Drug Conjugates Product Portfolio Table 57. Seattle Genetics Recent Developments Table 58. Progenics Pharmaceuticals Company Information Table 59. Progenics Pharmaceuticals Business Overview Table 60. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Portfolio Table 62. Progenics Pharmaceuticals Recent Developments Table 63. PDL BioPharma Company Information Table 64. PDL BioPharma Business Overview Table 65. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. PDL BioPharma Cancer Antibody Drug Conjugates Product Portfolio Table 67. PDL BioPharma Recent Developments Table 68. Nordic Nanovector Company Information Table 69. Nordic Nanovector Business Overview Table 70. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Nordic Nanovector Cancer Antibody Drug Conjugates Product Portfolio Table 72. Nordic Nanovector Recent Developments Table 73. Millennium Company Information Table 74. Millennium Business Overview Table 75. Millennium Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Millennium Cancer Antibody Drug Conjugates Product Portfolio Table 77. Millennium Recent Developments Table 78. Helix BioPharma Company Information Table 79. Helix BioPharma Business Overview Table 80. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Helix BioPharma Cancer Antibody Drug Conjugates Product Portfolio Table 82. Helix BioPharma Recent Developments Table 83. Bristol-Myers Squibb Company Information Table 84. Bristol-Myers Squibb Business Overview Table 85. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Portfolio Table 87. Bristol-Myers Squibb Recent Developments Table 88. Biotest AG Company Information Table 89. Biotest AG Business Overview Table 90. Biotest AG Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Biotest AG Cancer Antibody Drug Conjugates Product Portfolio Table 92. Biotest AG Recent Developments Table 93. Biogen Idec Company Information Table 94. Biogen Idec Business Overview Table 95. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Biogen Idec Cancer Antibody Drug Conjugates Product Portfolio Table 97. Biogen Idec Recent Developments Table 98. AbGenomics Corporation Company Information Table 99. AbGenomics Corporation Business Overview Table 100. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. AbGenomics Corporation Cancer Antibody Drug Conjugates Product Portfolio Table 102. AbGenomics Corporation Recent Developments Table 103. Global Cancer Antibody Drug Conjugates Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Cancer Antibody Drug Conjugates Sales by Region (2021-2026) & (K Units) Table 105. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2021-2026) Table 106. Global Cancer Antibody Drug Conjugates Sales by Region (2027-2032) & (K Units) Table 107. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2027-2032) Table 108. Global Cancer Antibody Drug Conjugates Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2021-2026) Table 110. Global Cancer Antibody Drug Conjugates Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2027-2032) Table 112. North America Cancer Antibody Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 114. North America Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 115. North America Cancer Antibody Drug Conjugates Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Cancer Antibody Drug Conjugates Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Cancer Antibody Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 119. Europe Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 120. Europe Cancer Antibody Drug Conjugates Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Cancer Antibody Drug Conjugates Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 124. Asia Pacific Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 125. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Cancer Antibody Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 129. South America Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 130. South America Cancer Antibody Drug Conjugates Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Cancer Antibody Drug Conjugates Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Cancer Antibody Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 138. Global Cancer Antibody Drug Conjugates Sales by Type (2027-2032) & (K Units) Table 139. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2021-2026) Table 140. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2027-2032) Table 141. Global Cancer Antibody Drug Conjugates Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Cancer Antibody Drug Conjugates Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2021-2026) Table 144. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2027-2032) Table 145. Global Cancer Antibody Drug Conjugates Price by Type (2021-2026) & (US$/Unit) Table 146. Global Cancer Antibody Drug Conjugates Price by Type (2027-2032) & (US$/Unit) Table 147. Global Cancer Antibody Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 148. Global Cancer Antibody Drug Conjugates Sales by Application (2027-2032) & (K Units) Table 149. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2021-2026) Table 150. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2027-2032) Table 151. Global Cancer Antibody Drug Conjugates Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Cancer Antibody Drug Conjugates Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2021-2026) Table 154. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2027-2032) Table 155. Global Cancer Antibody Drug Conjugates Price by Application (2021-2026) & (US$/Unit) Table 156. Global Cancer Antibody Drug Conjugates Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Cancer Antibody Drug Conjugates Distributors List Table 160. Cancer Antibody Drug Conjugates Customers List Table 161. Cancer Antibody Drug Conjugates Industry Trends Table 162. Cancer Antibody Drug Conjugates Industry Drivers Table 163. Cancer Antibody Drug Conjugates Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Cancer Antibody Drug Conjugates Product Image Figure 5. Global Cancer Antibody Drug Conjugates Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Cancer Antibody Drug Conjugates Market Size (2021-2032) & (US$ Million) Figure 7. Global Cancer Antibody Drug Conjugates Sales (2021-2032) & (K Units) Figure 8. Global Cancer Antibody Drug Conjugates Average Price (US$/Unit) & (2021-2032) Figure 9. First & Second Generation ADCs Product Image Figure 10. Third Generation ADCs Product Image Figure 11. Hospitals Product Image Figure 12. Clinics Product Image Figure 13. Others Product Image Figure 14. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Cancer Antibody Drug Conjugates, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Cancer Antibody Drug Conjugates Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Cancer Antibody Drug Conjugates Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Cancer Antibody Drug Conjugates Sales by Region in 2025 Figure 20. Global Cancer Antibody Drug Conjugates Revenue by Region in 2025 Figure 21. North America Cancer Antibody Drug Conjugates Market Size by Country in 2025 Figure 22. North America Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 23. North America Cancer Antibody Drug Conjugates Revenue Market Share by Country (2021-2032) Figure 24. United States Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Cancer Antibody Drug Conjugates Market Size by Country in 2025 Figure 27. Europe Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 28. Europe Cancer Antibody Drug Conjugates Revenue Market Share by Country (2021-2032) Figure 29. Germany Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Netherlands Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Nordic Countries Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Cancer Antibody Drug Conjugates Market Size by Country in 2025 Figure 36. Asia Pacific Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Cancer Antibody Drug Conjugates Revenue Market Share by Country (2021-2032) Figure 38. China Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Cancer Antibody Drug Conjugates Market Size by Country in 2025 Figure 47. South America Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 48. South America Cancer Antibody Drug Conjugates Revenue Market Share by Country (2021-2032) Figure 49. Mexico Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Middle East and Africa Cancer Antibody Drug Conjugates Market Size by Country in 2025 Figure 53. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 54. Middle East and Africa Cancer Antibody Drug Conjugates Revenue Market Share by Country (2021-2032) Figure 55. Turkey Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Saudi Arabia Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. UAE Cancer Antibody Drug Conjugates Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2021-2032) Figure 59. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2021-2032) Figure 60. Global Cancer Antibody Drug Conjugates Price (US$/Unit) by Type (2021-2032) Figure 61. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2021-2032) Figure 62. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2021-2032) Figure 63. Global Cancer Antibody Drug Conjugates Price (US$/Unit) by Application (2021-2032) Figure 64. Cancer Antibody Drug Conjugates Value Chain Figure 65. Cancer Antibody Drug Conjugates Production Mode & Process Figure 66. Direct Comparison with Distribution Share Figure 67. Distributors Profiles Figure 68. Cancer Antibody Drug Conjugates Industry Opportunities and Challenges

Scope & coverage.

Types
  • First & Second Generation ADCs
  • Third Generation ADCs
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Novartis
  • Merck
  • Roche
  • AbbVie
  • Viventia Biotechnologies
  • UCB
  • Stem CentRx
  • Seattle Genetics
  • Progenics Pharmaceuticals
  • PDL BioPharma
  • Nordic Nanovector
  • Millennium
  • Helix BioPharma
  • Bristol-Myers Squibb
  • Biotest AG
  • Biogen Idec
  • AbGenomics Corporation

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Cancer Antibody Drug Conjugates Market Size (2021-2032)
  4. 2.2.2 Global Cancer Antibody Drug Conjugates Sales (2021-2032)
  5. 2.2.3 Global Cancer Antibody Drug Conjugates Market Average Price (2021-2032)
  6. 2.3 Cancer Antibody Drug Conjugates by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 First & Second Generation ADCs
  9. 2.3.3 Third Generation ADCs
  10. 2.4 Cancer Antibody Drug Conjugates by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospitals
  13. 2.4.3 Clinics
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Cancer Antibody Drug Conjugates Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Cancer Antibody Drug Conjugates Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Cancer Antibody Drug Conjugates Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Cancer Antibody Drug Conjugates Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Cancer Antibody Drug Conjugates Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Cancer Antibody Drug Conjugates, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Cancer Antibody Drug Conjugates, Product Type & Application
  8. 3.8 Global Manufacturers of Cancer Antibody Drug Conjugates, Established Date
  9. 3.9 Global Cancer Antibody Drug Conjugates Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novartis
  2. 4.1.1 Novartis Company Information
  3. 4.1.2 Novartis Business Overview
  4. 4.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novartis Cancer Antibody Drug Conjugates Product Portfolio
  6. 4.1.5 Novartis Recent Developments
  7. 4.2 Merck
  8. 4.2.1 Merck Company Information
  9. 4.2.2 Merck Business Overview
  10. 4.2.3 Merck Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Merck Cancer Antibody Drug Conjugates Product Portfolio
  12. 4.2.5 Merck Recent Developments
  13. 4.3 Roche
  14. 4.3.1 Roche Company Information
  15. 4.3.2 Roche Business Overview
  16. 4.3.3 Roche Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Roche Cancer Antibody Drug Conjugates Product Portfolio
  18. 4.3.5 Roche Recent Developments
  19. 4.4 AbbVie
  20. 4.4.1 AbbVie Company Information
  21. 4.4.2 AbbVie Business Overview
  22. 4.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 AbbVie Cancer Antibody Drug Conjugates Product Portfolio
  24. 4.4.5 AbbVie Recent Developments
  25. 4.5 Viventia Biotechnologies
  26. 4.5.1 Viventia Biotechnologies Company Information
  27. 4.5.2 Viventia Biotechnologies Business Overview
  28. 4.5.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Portfolio
  30. 4.5.5 Viventia Biotechnologies Recent Developments
  31. 4.6 UCB
  32. 4.6.1 UCB Company Information
  33. 4.6.2 UCB Business Overview
  34. 4.6.3 UCB Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 UCB Cancer Antibody Drug Conjugates Product Portfolio
  36. 4.6.5 UCB Recent Developments
  37. 4.7 Stem CentRx
  38. 4.7.1 Stem CentRx Company Information
  39. 4.7.2 Stem CentRx Business Overview
  40. 4.7.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Stem CentRx Cancer Antibody Drug Conjugates Product Portfolio
  42. 4.7.5 Stem CentRx Recent Developments
  43. 4.8 Seattle Genetics
  44. 4.8.1 Seattle Genetics Company Information
  45. 4.8.2 Seattle Genetics Business Overview
  46. 4.8.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Seattle Genetics Cancer Antibody Drug Conjugates Product Portfolio
  48. 4.8.5 Seattle Genetics Recent Developments
  49. 4.9 Progenics Pharmaceuticals
  50. 4.9.1 Progenics Pharmaceuticals Company Information
  51. 4.9.2 Progenics Pharmaceuticals Business Overview
  52. 4.9.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Portfolio
  54. 4.9.5 Progenics Pharmaceuticals Recent Developments
  55. 4.10 PDL BioPharma
  56. 4.10.1 PDL BioPharma Company Information
  57. 4.10.2 PDL BioPharma Business Overview
  58. 4.10.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 PDL BioPharma Cancer Antibody Drug Conjugates Product Portfolio
  60. 4.10.5 PDL BioPharma Recent Developments
  61. 4.11 Nordic Nanovector
  62. 4.11.1 Nordic Nanovector Company Information
  63. 4.11.2 Nordic Nanovector Business Overview
  64. 4.11.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Nordic Nanovector Cancer Antibody Drug Conjugates Product Portfolio
  66. 4.11.5 Nordic Nanovector Recent Developments
  67. 4.12 Millennium
  68. 4.12.1 Millennium Company Information
  69. 4.12.2 Millennium Business Overview
  70. 4.12.3 Millennium Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Millennium Cancer Antibody Drug Conjugates Product Portfolio
  72. 4.12.5 Millennium Recent Developments
  73. 4.13 Helix BioPharma
  74. 4.13.1 Helix BioPharma Company Information
  75. 4.13.2 Helix BioPharma Business Overview
  76. 4.13.3 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Helix BioPharma Cancer Antibody Drug Conjugates Product Portfolio
  78. 4.13.5 Helix BioPharma Recent Developments
  79. 4.14 Bristol-Myers Squibb
  80. 4.14.1 Bristol-Myers Squibb Company Information
  81. 4.14.2 Bristol-Myers Squibb Business Overview
  82. 4.14.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Portfolio
  84. 4.14.5 Bristol-Myers Squibb Recent Developments
  85. 4.15 Biotest AG
  86. 4.15.1 Biotest AG Company Information
  87. 4.15.2 Biotest AG Business Overview
  88. 4.15.3 Biotest AG Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Biotest AG Cancer Antibody Drug Conjugates Product Portfolio
  90. 4.15.5 Biotest AG Recent Developments
  91. 4.16 Biogen Idec
  92. 4.16.1 Biogen Idec Company Information
  93. 4.16.2 Biogen Idec Business Overview
  94. 4.16.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Biogen Idec Cancer Antibody Drug Conjugates Product Portfolio
  96. 4.16.5 Biogen Idec Recent Developments
  97. 4.17 AbGenomics Corporation
  98. 4.17.1 AbGenomics Corporation Company Information
  99. 4.17.2 AbGenomics Corporation Business Overview
  100. 4.17.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Product Portfolio
  102. 4.17.5 AbGenomics Corporation Recent Developments
5 Global Cancer Antibody Drug Conjugates Market Scenario by Region
  1. 5.1 Global Cancer Antibody Drug Conjugates Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Cancer Antibody Drug Conjugates Sales by Region: 2021-2032
  3. 5.2.1 Global Cancer Antibody Drug Conjugates Sales by Region: 2021-2026
  4. 5.2.2 Global Cancer Antibody Drug Conjugates Sales by Region: 2027-2032
  5. 5.3 Global Cancer Antibody Drug Conjugates Revenue by Region: 2021-2032
  6. 5.3.1 Global Cancer Antibody Drug Conjugates Revenue by Region: 2021-2026
  7. 5.3.2 Global Cancer Antibody Drug Conjugates Revenue by Region: 2027-2032
  8. 5.4 North America Cancer Antibody Drug Conjugates Market Facts & Figures by Country
  9. 5.4.1 North America Cancer Antibody Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  11. 5.4.3 North America Cancer Antibody Drug Conjugates Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Cancer Antibody Drug Conjugates Market Facts & Figures by Country
  15. 5.5.1 Europe Cancer Antibody Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  17. 5.5.3 Europe Cancer Antibody Drug Conjugates Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Cancer Antibody Drug Conjugates Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Cancer Antibody Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Cancer Antibody Drug Conjugates Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Cancer Antibody Drug Conjugates Market Facts & Figures by Country
  36. 5.7.1 South America Cancer Antibody Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  38. 5.7.3 South America Cancer Antibody Drug Conjugates Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.8 Middle East and Africa Cancer Antibody Drug Conjugates Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Cancer Antibody Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Cancer Antibody Drug Conjugates Sales by Type (2021-2032)
  2. 6.1.1 Global Cancer Antibody Drug Conjugates Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2021-2032)
  4. 6.2 Global Cancer Antibody Drug Conjugates Revenue by Type (2021-2032)
  5. 6.2.1 Global Cancer Antibody Drug Conjugates Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Cancer Antibody Drug Conjugates Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Cancer Antibody Drug Conjugates Sales by Application (2021-2032)
  2. 7.1.1 Global Cancer Antibody Drug Conjugates Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2021-2032)
  4. 7.2 Global Cancer Antibody Drug Conjugates Revenue by Application (2021-2032)
  5. 7.2.1 Global Cancer Antibody Drug Conjugates Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Cancer Antibody Drug Conjugates Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Cancer Antibody Drug Conjugates Value Chain Analysis
  2. 8.1.1 Cancer Antibody Drug Conjugates Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Cancer Antibody Drug Conjugates Production Mode & Process
  5. 8.2 Cancer Antibody Drug Conjugates Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Cancer Antibody Drug Conjugates Distributors
  8. 8.2.3 Cancer Antibody Drug Conjugates Customers
9 Global Cancer Antibody Drug Conjugates Analyzing Market Dynamics
  1. 9.1 Cancer Antibody Drug Conjugates Industry Trends
  2. 9.2 Cancer Antibody Drug Conjugates Industry Drivers
  3. 9.3 Cancer Antibody Drug Conjugates Industry Opportunities and Challenges
  4. 9.4 Cancer Antibody Drug Conjugates Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst